Cargando…

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions

Detalles Bibliográficos
Autores principales:	Yu, Evan Y, Oh, William K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Invited Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023355/ https://www.ncbi.nlm.nih.gov/pubmed/24759585 http://dx.doi.org/10.4103/1008-682X.127813

Ejemplares similares

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer
por: Wilson, Elizabeth M
Publicado: (2014)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
por: Markowski, Mark C, et al.
Publicado: (2015)

National Consensus on Non-metastatic Castration-Resistant Prostate Cancer: more than just a snapshot
por: Reis, Leonardo Oliveira, et al.
Publicado: (2021)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

New immunotherapeutic paradigms for castration-resistant prostate cancer
por: Galluzzi, Lorenzo
Publicado: (2013)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
por: Luo, Jun
Publicado: (2016)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!
por: Van Praet, Charles, et al.
Publicado: (2021)

The role of glutamine metabolism in castration-resistant prostate cancer
por: Zhao, Bing, et al.
Publicado: (2023)

Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
por: Vlaeminck-Guillem, Virginie
Publicado: (2020)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Galectin-3 in Heart Failure: More Answers or More Questions?
por: Ahmad, Tariq, et al.
Publicado: (2012)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

There is more to NPH than lower body Parkinsonism
por: Oertel, Joachim M. K., et al.
Publicado: (2021)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer
por: Parent, Ephraim E., et al.
Publicado: (2022)

Influenza: one or two more questions
por: Robertson, Miranda
Publicado: (2009)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer
por: Xu, Jin, et al.
Publicado: (2019)

The C9ORF72 mutation brings more answers and more questions
por: Miller, Bruce L
Publicado: (2013)

Advances in gout: some answers, more questions
por: Singh, Jasvinder A
Publicado: (2010)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Glucocorticoids and Airway Smooth Muscle: A Few More Answers, Still More Questions
por: Nayak, Ajay P.
Publicado: (2019)

Rising Stroke Incidence in Young Adults: More Epidemiological Evidence, More Questions to Be Answered
por: Béjot, Yannick, et al.
Publicado: (2016)

More Dengue, More Questions
por: Halstead, Scott B.
Publicado: (2005)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

Bullying victimization and perpetration: some answers and more questions()
por: Voisin, Dexter R., et al.
Publicado: (2023)

Questions, Questions, Questions, and More Questions
por: Gillespie, Kay
Publicado: (2020)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Sexual dysfunction and prostate cancer risk: one more piece of a complex puzzle
por: Capogrosso, Paolo, et al.
Publicado: (2017)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h9oadqbsknomavdb8djgn8sk7m